Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 8/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220249 | 0.89 | CCR3 (1.00) | CCR3KMT2ADRD4DRD2DRD3 | |
| SCHEMBL6704121 | 0.87 | CCR3 (0.79) | CCR3 | |
| SCHEMBL6699954 | 0.84 | CCR3 (0.73) | CCR3KMT2ADRD4DRD2DRD3 | |
| SCHEMBL6705097 | 0.81 | CCR3 (1.00) | CCR3KMT2ADRD4DRD2DRD3 | |
| SCHEMBL6704940 | 0.79 | CCR3 (0.81) | CCR3KMT2AMEN1 | |
| SCHEMBL6701641 | 0.79 | CCR3 (1.00) | CCR3 | |
| SCHEMBL18658002 | 0.79 | CCR3 (0.78) | CCR3KMT2ADRD4DRD2DRD3 | |
| SCHEMBL12677059 | 0.78 | DRD4 (0.85) | CCR3KMT2ADRD4DRD2DRD3 | |
| SCHEMBL18657997 | 0.76 | ALDH1A1 (0.74) | CCR3KMT2ADRD4DRD2DRD3 | |
| SCHEMBL9078087 | 0.75 | DRD4 (1.00) | CCR3KMT2ADRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-08 | — | — | US | claimed |
| US-6492400-B1 | SUCH AS N-(2,5-DIFLUOROPHENYL)-N'-(2-((4-(PHENYLMETHYL)-1 -PIPERIDINYL)METHYL)PHENYL)UREA; PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | claimed |
| US-6780857-B2 | FOR TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES SUCH AS ASTHMA AND ALLERGIC DISEASES, AS WELL AS AUTOIMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-08 | — | — | US | disclosed |
| US-6492400-B1 | SUCH AS N-(2,5-DIFLUOROPHENYL)-N'-(2-((4-(PHENYLMETHYL)-1 -PIPERIDINYL)METHYL)PHENYL)UREA; PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885KMT2A 4287/4885DRD4 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.